RHAPSIDO
As listed in the register: RHAPSIDO
25 mg · tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Remibrutinib
- Made by
- Novartis Pharmaceuticals Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Spain1 matching products
Netherlands1 matching products
Details
| Made by | Novartis Pharmaceuticals Canada Inc |
|---|---|
| Active substance | Remibrutinib |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 25 mg |
| Form | tablet |
| Classification | L04AA60 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Approved |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02570076 |
| DPD drug code | 107225 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.